Join Growin Stock Community!
Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-flow-chart

RXRX Cash Flow

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, RXRX's operating cash flow stood at -$81.1M USD, reflecting a moderate deterioration from the previous quarter's -$46.1M USD in Q4'25 but remaining less severe than the peak negative of -$131.96M USD in Q1'25. Free cash flow for the same period was -$81.4M USD, closely mirroring operating cash flow and indicating ongoing capital expenditures that continue to pressure liquidity. Over the period from Q2'23 to Q1'26, both operating and free cash flows have exhibited a consistently negative trend with high volatility, starting at around -$67.5M USD and -$71.4M USD respectively in Q2'23, and worsening to lows of -$133.8M USD for free cash flow in Q1'25 amid apparent expansion efforts. Notable improvements occurred in Q3'24 (-$59.2M USD operating) and Q4'25 (-$46.1M USD operating), suggesting intermittent cost controls, though the overall pattern underscores persistent cash burn typical of growth-stage biotech firms, with free cash flow averaging 2-5% more negative than operating due to steady investments.